News for Tryp Therapeutics Inc. (TRYP.CN)

Tryp Therapeutics, Inc. announces, that it has filed amended financial statements for the six months ended February 29, 2024 , along with the corresponding Management Discussion & Analysis . The...

Company to be in San Francisco January 8-11, 2023, during 41st Annual J.P. Morgan Health Care Conference

KELOWNA, British Columbia, Dec. 13, 2022 (GLOBE NEWSWIRE) —

KELOWNA, British Columbia, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company...

Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on...

Enables Potentially Scalable Model For The Broad Roll-Out of Psychedelic Treatments

KELOWNA, British Columbia, Sept. 26, 2022 (GLOBE NEWSWIRE) —

KELOWNA, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp" or the "Company"), a clinical-stage...

KELOWNA, British Columbia, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a...

Tryp’s Phase II Study of the Treatment of Overeating utilizing Psilocybin (STOP) trial in collaboration with the University of Florida, represents the first use of psilocybin in conjunction with psychotherapy as a therapeutic intervention in patients with BED.

Tryp Therapeutics a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced that Albany Molecular Research has... | February 16, 2021

As the psychedelics industry continues to grow, the Investing News Network offers a growing list of publicly traded psychedelics stocks.